Artal Group’s LAVA Therapeutics LVTX Stock Holding History

Artal Group’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,000	Closed	-$294K	–	105
2023 Q3	$294K	Hold	200,000	–	–	0.01%	92
2023 Q2	$406K	Hold	200,000	–	–	0.01%	106
2023 Q1	$332K	Hold	200,000	–	–	0.02%	108
2022 Q4	$700K	Hold	200,000	–	–	0.04%	112
2022 Q3	$914K	Hold	200,000	–	–	0.05%	116
2022 Q2	$590K	Hold	200,000	–	–	0.03%	119
2022 Q1	$880K	Hold	200,000	–	–	0.04%	126
2021 Q4	$1.1M	Hold	200,000	–	–	0.03%	139
2021 Q3	$1.18M	Hold	200,000	–	–	0.03%	140
2021 Q2	$2.18M	Hold	200,000	–	–	0.05%	136
2021 Q1	$3.04M	Buy	+200,000	New	+$2.75M	0.06%	133

Other funds holding LVTX

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

PNC Financial Services Group

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return